Literature DB >> 29676943

Impact of preoperative thrombocytopenia on the outcome after coronary artery bypass grafting.

Wail Nammas1, Magnus Dalén2, Stefano Rosato3, Riccardo Gherli4, Daniel Reichart5, Giuseppe Gatti6, Francesco Onorati7, Giuseppe Faggian7, Marisa De Feo8, Ciro Bancone8, Sidney Chocron9, Sorosh Khodabandeh2, Giuseppe Santarpino10, Antonino S Rubino11, Daniele Maselli12, Saverio Nardella12, Antonio Salsano13, Tiziano Gherli14, Francesco Nicolini14, Marco Zanobini15, Matteo Saccocci15, Karl Bounader16, Paola D'Errigo3, Tuomas Kiviniemi1, Eeva-Maija Kinnunen17, Andrea Perrotti9, Juhani Airaksinen1, Giovanni Mariscalco18, Vito G Ruggieri19, Fausto Biancari1,17,20.   

Abstract

The impact of thrombocytopenia on postoperative bleeding and other major adverse events after cardiac surgery is unclear. This issue was investigated in a series of patients who underwent isolated coronary artery bypass grafting (CABG) from the prospective, multicenter E-CABG registry. Preoperative thrombocytopenia was defined as preoperative platelet count <150 × 109/L and it was considered moderate-severe when preoperative platelet count was <100 × 109/L. Multilevel mixed-effects regression analysis was performed to adjust the effect of thrombocytopenia on outcomes for baseline and operative covariates as well as for interinstitutional differences in patient-blood management. Among 7189 patients included in this analysis, 599 (8.3%) had preoperative thrombocytopenia. Patient with preoperative thrombocytopenia had an increased chest drainage output at 12 h (mean, 519 vs. 456 mL, adjusted coeff. 39, 95%CI 18-60) and rates of severe-massive bleeding (Universal Definition of Perioperative Bleeding (UDPB) severity grades 3-4: 12.7% vs. 8.1%, adjusted OR 1.47, 95%CI 1.11-1.93; E-CABG bleeding severity grades 2-3: 10.4% vs. 6.1%, adjusted OR 1.78, 95%CI 1.30-2.43). Thrombocytopenia was associated with an increased risk of hospital/30-day death (3.2% vs. 1.9%, adjusted OR 2.02, 95%CI 1.20-3.42), 1-year death (5.7% vs. 3.4%, adjusted HR 1.68, 95%CI 1.16-2.44), deep sternal wound infection (3.5% vs. 2.4%, adjusted OR 1.65, 95%CI 1.02-2.66), acute kidney injury (28.1% vs. 22.2%, OR 1.45, 1.18-1.78), and prolonged stay in the intensive care unit (mean, 3.6 vs 2.8 days, adjusted coeff. 0.74, 95%CI 0.40-1.09). Similar results were observed in a subset of patients with moderate-severe thrombocytopenia (51 patients, 0.7%). In particular, these patients had a markedly higher rate of acute kidney injury (40%, adjusted OR, 1.94, 95%CI 1.05-3.57), resternotomy for bleeding (7.8%, adjusted OR 3.49, 95%CI 1.20-10.21), and severe-massive bleeding (UDPB severity grades 3-4: 23.5%, adjusted OR 3.08, 95%CI 1.52-6.22; E-CABG bleeding severity grades 2-3: 23.5%, adjusted OR 4.43, 95%CI 2.15-9.15) compared to patients with normal preoperative platelet count. Mild preoperative thrombocytopenia is associated with increased risk of severe-massive bleeding, mortality, and other major adverse events after CABG. Such risks are markedly increased in patients with moderate-severe preoperative thrombocytopenia.

Entities:  

Keywords:  Bleeding; cardiac surgery; coronary artery bypass grafting; platelets; surgery; thrombocytopenia

Mesh:

Year:  2018        PMID: 29676943     DOI: 10.1080/09537104.2018.1466389

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  2 in total

1.  Can C-reactive protein predict coagulation in off pump coronary artery bypass grafting? A cohort study.

Authors:  Xiaojie Liu; Yang Yu; Lijuan Wang; Sudena Wang; Yuchen Gao; Hushan Ao
Journal:  J Cardiothorac Surg       Date:  2022-09-02       Impact factor: 1.522

2.  Preoperative platelet count, preoperative hemoglobin concentration and deep hypothermic circulatory arrest duration are risk factors for acute kidney injury after pulmonary endarterectomy: a retrospective cohort study.

Authors:  Congya Zhang; Guyan Wang; Hui Zhou; Guiyu Lei; Lijing Yang; Zhongrong Fang; Sheng Shi; Jun Li; Zhiyan Han; Yunhu Song; Sheng Liu
Journal:  J Cardiothorac Surg       Date:  2019-12-30       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.